Los Angeles Capital Management LLC Trims Stake in Replimune Group, Inc. (NASDAQ:REPL)

Los Angeles Capital Management LLC trimmed its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 41.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,547 shares of the company's stock after selling 24,040 shares during the quarter. Los Angeles Capital Management LLC owned 0.05% of Replimune Group worth $418,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Baker BROS. Advisors LP raised its holdings in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Braidwell LP boosted its holdings in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock worth $33,656,000 after buying an additional 2,057,460 shares during the period. State Street Corp lifted its position in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after acquiring an additional 217,308 shares during the period. Finally, Parkman Healthcare Partners LLC increased its position in Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock worth $8,371,000 after buying an additional 238,747 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. BMO Capital Markets upped their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, HC Wainwright lifted their price target on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Replimune Group presently has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Trading Down 0.1 %

NASDAQ REPL traded down $0.01 during trading hours on Friday, reaching $11.73. The company's stock had a trading volume of 198,203 shares, compared to its average volume of 868,724. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The firm has a fifty day simple moving average of $12.75 and a 200-day simple moving average of $12.04. The stock has a market cap of $903.39 million, a P/E ratio of -3.82 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.